More tools:Markets·Screener·Research·Chat

Tarsus Pharmaceuticals, Inc. Common Stock (TARS) Financial Statements

Tarsus Pharmaceuticals, Inc. Common Stock
SIC 2836 · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
FIGI BBG00RB9BNR6
XNAS · usd
87.22▼ 3.56 (-3.92%)
As of 2026-09-08
Valuation
Market Cap
Enterprise Value
Trailing P/E—
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close90.78
Day's Range87.01 – 90.75
52-Week Range48.20 – 91.53
Volume1.8M
Avg Volume783.9K
Share Statistics
Shares Outstanding
Employees370
ExchangeXNAS
Listed2020-10-16
Share count as of July 30, 2026
Loading Income Statement…
Key questions about Tarsus Pharmaceuticals, Inc. Common Stock (TARS)
What is Tarsus Pharmaceuticals, Inc. Common Stock's Market Cap?
Tarsus Pharmaceuticals, Inc. Common Stock's Market Cap is $3.8B, based on as-reported figures from SEC (XBRL) filings.
What is Tarsus Pharmaceuticals, Inc. Common Stock's Enterprise Value?
Tarsus Pharmaceuticals, Inc. Common Stock's Enterprise Value is $3.5B, based on as-reported figures from SEC (XBRL) filings.
What is Tarsus Pharmaceuticals, Inc. Common Stock's Price / Sales?
Tarsus Pharmaceuticals, Inc. Common Stock's Price / Sales is 6.3×, based on as-reported figures from SEC (XBRL) filings.
What is Tarsus Pharmaceuticals, Inc. Common Stock's EV / Revenue?
Tarsus Pharmaceuticals, Inc. Common Stock's EV / Revenue is 5.7×, based on as-reported figures from SEC (XBRL) filings.
What is Tarsus Pharmaceuticals, Inc. Common Stock's EV / EBITDA?
Tarsus Pharmaceuticals, Inc. Common Stock's EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is Tarsus Pharmaceuticals, Inc. Common Stock's Revenue (TTM)?
Tarsus Pharmaceuticals, Inc. Common Stock's Revenue (TTM) is $606.3M, based on as-reported figures from SEC (XBRL) filings.
What is Tarsus Pharmaceuticals, Inc. Common Stock's Net Income (TTM)?
Tarsus Pharmaceuticals, Inc. Common Stock's Net Income (TTM) is -$46.5M, based on as-reported figures from SEC (XBRL) filings.
What is Tarsus Pharmaceuticals, Inc. Common Stock's EBITDA?
Tarsus Pharmaceuticals, Inc. Common Stock's EBITDA is -$46.2M, based on as-reported figures from SEC (XBRL) filings.
What is Tarsus Pharmaceuticals, Inc. Common Stock's Diluted EPS (TTM)?
Tarsus Pharmaceuticals, Inc. Common Stock's Diluted EPS (TTM) is -1.06, based on as-reported figures from SEC (XBRL) filings.
What is Tarsus Pharmaceuticals, Inc. Common Stock's EBITDA Margin?
Tarsus Pharmaceuticals, Inc. Common Stock's EBITDA Margin is -7.6%, based on as-reported figures from SEC (XBRL) filings.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Revenues:
Total revenues
YoY growth+69.4%+106.9%+128.4%+146.7%
Operating expenses:
Cost of sales
Research and development
Selling, general and administrative
Total operating expenses
% of revenue111.4%103.8%105.3%112.2%
Loss from operations before other income (expense)
% of revenue-11.4%-3.8%-5.3%-12.2%
Other income (expense):
Interest income
Interest expense
Gain on exchange of long-term investments———
Other income (expense), net
Total other income (expense), net
Provision for income taxes——
Net loss
% of revenue-10.7%-4.3%-5.5%-10.6%
Net loss per share - basic (usd per share)
Net loss per share - diluted (usd per share)